NEW YORK (GenomeWeb News) – PerkinElmer reported after the close of the market Thursday that its first-quarter revenues increased 7 percent, with a 4 percent benefit from acquisitions and a 1 percent contribution from acquisitions.
The Waltham, Mass.-based firm reported total revenues of $465.1 million for the three-month period ended April 4, compared to $435.2 million for the first quarter of 2009. Sales for its Human Health segment increased 6 percent to $188.6 million from $177.3 million, while sales for its Environmental Health segment increased 19 percent to $276.5 million from $257.9 million.
The firm surpassed analysts' consensus expectations for revenues of $446.8 million.
PerkinElmer posted a profit of $24.4 million, or $.21 per share, compared to $10.6 million, or $.09 per share, for the first quarter of 2009. Its adjusted EPS was $.31, beating analysts' consensus estimate of $.29.
The firm's R&D spending rose 3 percent to $27.1 million from $26.2 million, while its SG&A spending increased around 2 percent to $132.1 million from $129.1 million.
PerkinElmer finished the quarter with $181.7 million in cash and cash equivalents.
The firm expects its full-year 2010 GAAP EPS to be between $1.08 and $1.13, and non-GAAP EPS of between $1.43 and $1.48.